Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

While poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have achieved specific clinical benefits in a subset of pancreatic ductal adenocarcinoma (PDAC) patients, the potential role of the PARPi niraparib in PDAC necessitates further exploration. In this study, we demonstrated that Ni...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-01-01
סדרה:	Translational Oncology
נושאים:	Pancreatic ductal adenocarcinoma Niraparib Autophagy Gemcitabine-resistance
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S1936523324003334
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!